Minaris Advanced Therapies

Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Find alternatives to Minaris Advanced Therapies for CAR-T →
Program data pending ClinicalTrials.gov matching · Last scored 2026-11-02
83.1
Signal Score
✓ FDA Inspections (3) ○ Clinical Trials ○ SEC Filings ✓ Press (3) ✓ EMA GMP (2) ○ MHRA GMP ✓ HC GMP (9)

Quick Facts: Minaris Advanced Therapies

Signal Score
83.1/100 (as of 2026-11-02)
Quality Compliance
99.2/100
Headquarters
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Modalities
CAR-T, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Minaris Advanced Therapies

Merged WuXi AT + PCT/Hitachi. Acquired by Altaris from WuXi AppTec (2024).

Signal Score & Pillar Breakdown

Quality Compliance 99.2
FDA Inspections3 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-11-25)
EMA GMP Certificates2 on record
Most Recent HC OutcomeCompliant · 2025-03-19
HC Attribution9 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Altaris Capital Partners
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Altaris Capital Partners
Financial assessment: 68.0/100
Capacity 70.0
Multi-site operations (4 manufacturing sites)
Sites: Philadelphia, PA, Allendale, NJ, Yokohama, Japan, Munich, Germany
Source: company profiles (manufacturing sites, modality breadth)
4 manufacturing sites
StatusLimited
Multi-site operations (4 manufacturing sites)
Sites: Philadelphia, PA, Allendale, NJ, Yokohama, Japan, Munich, Germany
Press Signals3 articles (not scored)
Multi-site operations (4 manufacturing sites)

Minaris Advanced Therapies FDA Inspection History

2025-11
2025-09
2025-02
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-11-25
Advanced Therapies LLC
Philadelphia, Pennsylvania Company-level
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2025-09-29
Minaris Regenerative Medicine, LLC
Allendale, New Jersey Facility-linked
Human Cellular, Tissue, and Gene Therapies Yes Voluntary Action Indicated (VAI)
2025-02-07
Advanced Therapies LLC
Philadelphia, Pennsylvania Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Attribution not established (2)
These records are excluded from this company’s established evidence because their attribution is unresolved. This describes an evidence-linking limitation, not an assessment of the underlying regulatory findings.
Source Establishment named by the regulator Location Identifier
MHRA GMP certificate WUXI APPTEC INCORPORATED 19112 —
MHRA GMP certificate WUXI APPTEC INCORPORATED 19112 —
Source records retained verbatim · attribution not established

Minaris Advanced Therapies FDA 483 Findings 3 observations · 2025-09-29 → 2025-09-29 ?

By subsystem

  • Documentation & Records 2 (66.7%)
  • Equipment & Facilities 1 (33.3%)

By severity

  • 2 — Minor: 3
  • Repeat observations: 0

Most severe findings

  • Minor (2) Equipment & Facilities 2025-09-29 21 CFR 211.188(b)(2)
    Identity of major equipment and lines used

    "Batch production and control records do not include the identity of individual major equipment used for each batch of drug product produced."

  • Minor (2) Documentation & Records 2025-09-29 21 CFR 314.80(b)
    Failure to develop written procedures

    "Written procedures have not been developed for the receipt and evaluation of post marketing adverse drug experiences."

  • Minor (2) Documentation & Records 2025-09-29 21 CFR 211.100(a)
    Absence of Written Procedures

    "Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess."

Minaris Advanced Therapies EMA GMP Compliance 2 certificates

2025-07
2024-02
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_BY_04_GMP_2026_0001 MINARIS Regenerative Medicine GmbH Germany 2025-07-30 COMPLIANT
DE_BY_04_GMP_2026_0002 MINARIS Regenerative Medicine GmbH Germany 2024-02-08 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

biologics · 1 site

  • Philadelphia, United States · Advanced Therapies, LLC — biologics · valid to Jul 5, 2030
Previously accredited (cancelled) · 1
  • Allendale, United States · Minaris Regenerative Medicine, LLC — cell and gene therapy (CGT) · expired Sep 23, 2026

No longer on PMDA's current list. Shown for history only; not used in search tags.

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Company Signals 3 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-09-29
Minaris Evolves Business Model with Addition of Dedicated Viral Vectors Business Unit - PR Newswire
Minaris Evolves Business Model with Addition of Dedicated Viral Vectors Business Unit  PR Newswire
general 2026-03-23
Minaris Advanced Therapies launches new manufacturing facility in Munich - MSN
Minaris Advanced Therapies launches new manufacturing facility in Munich  MSN
general 2026-03-04
Minaris Unveils GMP-Grade NGS to Redefine Viral Safety Testing for Biologics and Advanced Therapies - BioBuzz
Minaris Unveils GMP-Grade NGS to Redefine Viral Safety Testing for Biologics and Advanced Therapies  news.biobuzz.io

Frequently Asked Questions About Minaris Advanced Therapies

How many FDA inspections does Minaris Advanced Therapies have on record?
CDMO Signal tracks 3 FDA inspections for Minaris Advanced Therapies, sourced from the FDA inspection database. See the full inspection history above.
Has Minaris Advanced Therapies received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Minaris Advanced Therapies.
Does Minaris Advanced Therapies hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 EMA GMP certificates for Minaris Advanced Therapies.
What is Minaris Advanced Therapies's CDMO Signal Score?
Minaris Advanced Therapies has a Signal Score of 83/100, based on quality, operations, financial stability, and capacity data.
Evaluating Minaris Advanced Therapies for a manufacturing program?
Use the free AI matchmaker to compare Minaris Advanced Therapies against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 79.3
CAR-T, Cell Therapy, iPSC, Gene Editing

Compare Minaris Advanced Therapies with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Minaris Advanced Therapies
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.